TG Therapeutics (TGTX) Aperçu de l'action
TG Therapeutics, Inc. est une société biopharmaceutique à vocation commerciale qui se concentre sur l'acquisition, le développement et la commercialisation de nouveaux traitements pour les maladies à médiation cellulaire aux États-Unis et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 5/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
TGTX Community Fair Values
Create NarrativeSee what 125 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
TG Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$33.85 |
| Plus haut sur 52 semaines | US$40.99 |
| Plus bas sur 52 semaines | US$25.28 |
| Bêta | 1.76 |
| Variation sur 1 mois | 0.95% |
| Variation sur 3 mois | 15.02% |
| Variation sur 1 an | -22.08% |
| Variation sur 3 ans | -1.28% |
| Variation sur 5 ans | -15.80% |
| Évolution depuis l'introduction en bourse | 2,879.09% |
Nouvelles et mises à jour récentes
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Apr 19TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.
TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.Recent updates
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Apr 19TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence
Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside
Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views
Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook
Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance
Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery
TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.
TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time
Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip
Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption
Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Oct 23
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market
Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
Sep 30Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)
Jul 29TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 16TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Mar 14TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics: Less Room For Doubt About Briumvi
May 03Rendement pour les actionnaires
| TGTX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -7.6% | -2.5% | 0.8% |
| 1Y | -22.1% | 26.8% | 27.7% |
Rendement vs Industrie: TGTX a sous-performé le secteur US Biotechs qui a rapporté 26.8 % au cours de l'année écoulée.
Rendement vs marché: TGTX a sous-performé le marché US qui a rapporté 27.7 % au cours de l'année écoulée.
Volatilité des prix
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Cours de l'action stable: TGTX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de TGTX ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1993 | 399 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc. est une société biopharmaceutique commerciale qui se concentre sur l'acquisition, le développement et la commercialisation de nouveaux traitements pour les maladies à médiation cellulaire B aux États-Unis et à l'étranger. La société propose BRIUMVI, un anticorps monoclonal anti-CD20 pour le traitement des patients adultes atteints de formes récurrentes de sclérose en plaques (RMS), y compris le syndrome cliniquement isolé, la maladie récurrente-rémittente et la maladie progressive secondaire active chez les adultes. Le pipeline de développement de la société comprend l'Ublituximab IV, un AcM anti-CD20 modifié génétiquement pour le traitement de la sclérose en plaques récurrente ; TG-1701 est un inhibiteur de la tyrosine kinase de Bruton (BTK) disponible par voie orale et lié de manière covalente, qui présente une sélectivité pour la BTK dans le criblage de la kinase in vitro ; et TG-1801, un anticorps bispécifique de CD47 et CD19.
TG Therapeutics, Inc. Résumé des fondamentaux
| TGTX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$5.00b |
| Bénéfices(TTM) | US$447.18m |
| Recettes(TTM) | US$616.29m |
Le site TGTX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| TGTX compte de résultat (TTM) | |
|---|---|
| Recettes | US$616.29m |
| Coût des recettes | US$100.71m |
| Marge brute | US$515.57m |
| Autres dépenses | US$68.39m |
| Les revenus | US$447.18m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 06, 2026
| Résultat par action (EPS) | 3.03 |
| Marge brute | 83.66% |
| Marge bénéficiaire nette | 72.56% |
| Ratio dettes/capitaux propres | 38.0% |
Quelles ont été les performances à long terme de TGTX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/02 04:29 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
TG Therapeutics, Inc. est couverte par 18 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |